ADMA Biologics Inc (NASDAQ:ADMA) Sees Significant Decrease in Short Interest

ADMA Biologics Inc (NASDAQ:ADMA) was the recipient of a significant decrease in short interest in the month of March. As of March 31st, there was short interest totaling 22,175,506 shares, a decrease of 14.1% from the March 15th total of 25,826,838 shares. Currently, 9.6% of the company’s shares are sold short. Based on an average daily volume of 13,551,247 shares, the days-to-cover ratio is presently 1.6 days.

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $10.74 on Friday. The stock has a fifty day moving average of $13.56 and a 200 day moving average of $15.82. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $25.67. The firm has a market capitalization of $2.56 billion, a price-to-earnings ratio of 17.90 and a beta of 0.82. The company has a quick ratio of 3.74, a current ratio of 6.71 and a debt-to-equity ratio of 0.16.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The company had revenue of $139.16 million during the quarter, compared to analyst estimates of $139.80 million. During the same quarter last year, the firm posted $0.46 earnings per share. The firm’s revenue was up 18.4% on a year-over-year basis. As a group, research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $15.63, for a total transaction of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares of the company’s stock, valued at approximately $7,292,958. This represents a 2.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were bought at an average cost of $15.67 per share, with a total value of $109,690.00. Following the purchase, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. This trade represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 3.50% of the company’s stock.

Institutional Trading of ADMA Biologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC lifted its stake in ADMA Biologics by 16.4% in the first quarter. SG Americas Securities LLC now owns 70,160 shares of the biotechnology company’s stock worth $632,000 after acquiring an additional 9,908 shares during the period. Rockefeller Capital Management L.P. lifted its stake in ADMA Biologics by 60.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 4,485 shares of the biotechnology company’s stock worth $82,000 after acquiring an additional 1,694 shares during the period. Corient Private Wealth LLC lifted its stake in ADMA Biologics by 58.0% in the fourth quarter. Corient Private Wealth LLC now owns 91,367 shares of the biotechnology company’s stock worth $1,667,000 after acquiring an additional 33,541 shares during the period. Vident Advisory LLC lifted its stake in ADMA Biologics by 24.2% in the fourth quarter. Vident Advisory LLC now owns 270,492 shares of the biotechnology company’s stock worth $4,934,000 after acquiring an additional 52,687 shares during the period. Finally, First Citizens Bank & Trust Co. raised its holdings in ADMA Biologics by 24.4% in the fourth quarter. First Citizens Bank & Trust Co. now owns 48,763 shares of the biotechnology company’s stock worth $889,000 after purchasing an additional 9,576 shares in the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Mizuho dropped their price objective on ADMA Biologics from $30.00 to $24.00 and set an “outperform” rating for the company in a research note on Monday. Zacks Research raised ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 2nd. Wall Street Zen raised ADMA Biologics from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of ADMA Biologics in a research note on Tuesday, December 23rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $28.00.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.